Introduction

Acute bacterial skin and skin structure infections (ABSSSI) are among the most frequent infectious diseases. Recently, several new antibiotics with activity against MRSA have been approved. Tedizolid, a second-generation oxazolidinone approved for ABSSSI offers theoretical advantages over first-generation oxazolidinones.

Areas covered

A comprehensive online search of Medline, ClinicalTrials.gov, and conference presentations was made, selecting articles between January 2000 and April 2020. In this review, the authors discuss the chemical and microbiological properties of tedizolid, summarize its efficacy, safety, and potential role in the treatment of ABSSSI as well as the potential for future indications.

Expert opinion

Tedizolid has proven to be non-inferior compared to linezolid for the treatment of ABSSSI in two registrational phase III clinical trials, being well tolerated. Tedizolid exhibits antibacterial activity against the most important ABSSSI pathogens (including multidrug-resistant strains of MRSA), as well as mycobacteria and Nocardia. It appears to have a safe profile, including decreased myelotoxicity and no significant drug interactions. Preliminary studies with longer duration of therapy seem to confirm these potential benefits. Overall, tedizolid expands the newly acquired armamentarium to treat ABSSSI. The role of tedizolid for other indications is under investigation and has yet to be determined.

中文翻译：

---

Tedizolid (torezolid) 用于治疗复杂的皮肤和皮肤结构感染。

介绍

急性细菌性皮肤和皮肤结构感染 (ABSSSI) 是最常见的传染病之一。最近，已经批准了几种具有抗 MRSA 活性的新抗生素。Tedizolid 是一种批准用于 ABSSSI 的第二代恶唑烷酮，与第一代恶唑烷酮相比具有理论优势。

涵盖的领域

对 Medline、ClinicalTrials.gov 和会议报告进行了全面的在线搜索，选择了 2000 年 1 月至 2020 年 4 月之间的文章。在这篇综述中，作者讨论了泰地唑胺的化学和微生物特性，总结了其疗效、安全性和潜在作用ABSSSI 的治疗以及未来适应症的潜力。

专家意见

在两项注册的 III 期临床试验中，与利奈唑胺相比，Tedizolid 已被证明不劣于治疗 ABSSSI，且耐受性良好。Tedizolid 对最重要的 ABSSSI 病原体（包括耐多药 MRSA 菌株）以及分枝杆菌和诺卡氏菌具有抗菌活性。它似乎具有安全性，包括降低骨髓毒性和没有显着的药物相互作用。具有较长治疗时间的初步研究似乎证实了这些潜在的益处。总体而言，泰地唑胺扩大了新收购的医疗器械以治疗 ABSSSI。泰地唑胺对其他适应症的作用正在研究中，尚未确定。